Molecular and in vivo studies of a glutamate-class prolyl-endopeptidase for coeliac disease therapy

Nat Commun. 2022 Aug 1;13(1):4446. doi: 10.1038/s41467-022-32215-1.

Abstract

The digestion of gluten generates toxic peptides, among which a highly immunogenic proline-rich 33-mer from wheat α-gliadin, that trigger coeliac disease. Neprosin from the pitcher plant is a reported prolyl endopeptidase. Here, we produce recombinant neprosin and its mutants, and find that full-length neprosin is a zymogen, which is self-activated at gastric pH by the release of an all-β pro-domain via a pH-switch mechanism featuring a lysine plug. The catalytic domain is an atypical 7+8-stranded β-sandwich with an extended active-site cleft containing an unprecedented pair of catalytic glutamates. Neprosin efficiently degrades both gliadin and the 33-mer in vitro under gastric conditions and is reversibly inactivated at pH > 5. Moreover, co-administration of gliadin and the neprosin zymogen at the ratio 500:1 reduces the abundance of the 33-mer in the small intestine of mice by up to 90%. Neprosin therefore founds a family of eukaryotic glutamate endopeptidases that fulfils requisites for a therapeutic glutenase.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Celiac Disease* / drug therapy
  • Celiac Disease* / genetics
  • Enzyme Precursors
  • Gliadin / chemistry
  • Gliadin / metabolism
  • Glutamic Acid
  • Glutens / chemistry
  • Mice
  • Prolyl Oligopeptidases
  • Sarraceniaceae / enzymology

Substances

  • Enzyme Precursors
  • Glutamic Acid
  • Glutens
  • Gliadin
  • Prolyl Oligopeptidases